Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-EGFR-IL13Rα2 Cells in EGFR-Amplified Recurrent Glioblastoma
NCT07209241Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Dec 2025
- Primary completion
- Nov 2042
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of bivalent CAR-T (anti-EGFR) in glioblastoma (GBM) (3 arms), sponsored by University of Pennsylvania. Primary endpoints: Adverse Events at 15 years and Dose-Limiting Toxicities at 28 days. Started Dec 2025; status: active, not recruiting.
02
Drugs
bivalent CAR-T (anti-EGFR)
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07209241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209241.